| Trial ID: | L1000 |
| Source ID: | NCT03129113
|
| Associated Drug: |
MAraViroc
|
| Title: |
Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV
|
| Acronym: |
MAVMET
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Hepatic Steatosis|HIV-1-infection
|
| Interventions: |
Drug: Maraviroc|Drug: Metformin
|
| Outcome Measures: |
Change in percentage of liver fat as measured by MR PDFF between baseline and week 48.
|
| Sponsor/Collaborators: |
University College, London|Medical Research Council|ViiV Healthcare|Royal Free Hospital NHS Foundation Trust
|
| Gender: |
All
|
| Age: |
35 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 2/Phase 3
|
| Enrollment: |
90
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
March 1, 2017
|
| Completion Date: |
November 6, 2020
|
| Results First Posted: |
--
|
| Last Update Posted: |
November 4, 2021
|
| Locations: |
Royal London Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|St Mary's Hospital, London, United Kingdom|UCL Mortimer Market Centre, London, United Kingdom
|
| URL: |
https://ClinicalTrials.gov/show/NCT03129113
|
